The elevated circulating concentration of endothelial microparticles (MPs) may provide an index of the extent and nature of cellular damage in chronic stroke. The purpose of this study was to determine the circulating concentrations of CD31 + /CD42b − , CD62E + and CD34 + MPs in chronic stroke subjects, focusing on the effects of chronic stroke by comparison with both older adults without a history of stroke but with type 2 diabetes mellitus (T2DM) and older and young healthy controls. Plasma from three groups of sedentary older (50-75 years) men and women (chronic stroke, T2DM or older healthy) as well as a group of younger (18-39 years) healthy controls was isolated from fasting blood, and CD31 + /CD42b − , CD62E + and CD34 + MPs were quantified using flow cytometry (n = 17/group). Concentrations of CD31 + /CD42b − and CD62E + MPs were higher in the T2DM group (P < 0.05), but not chronic stroke, compared to older and younger healthy adults. CD62E + MP and CD34 + MP concentrations were elevated in the older compared to younger adults (P < 0.05 for both). Sub-analyses excluding chronic stroke subjects who were also diagnosed with diabetes [stroke (diabetes − )] revealed lower CD31 + /CD42b − (P < 0.05) and CD62E + (P = 0.08) MPs in the stroke (diabetes − ) group compared to the T2DM group. CD31 + /CD42b − MP and CD62E + MP concentrations were each associated with fasting glucose levels and CD31 + /CD42b − MPs also were associated with triglyceride levels. As MPs have been proposed as potential targets for diagnosing, treating and identifying the clinical progression of T2DM, our study provides further support for the use of CD31 + /CD42b − and CD62E + MPs in the clinical progression of T2DM and associated vascular complications.
INTRODUCTION
Cardiovascular disease (CVD) including stroke is the leading cause of death in developed countries but only ∼50% of CV events can be explained by traditional biomarkers such as hypercholesterolaemia and hypertension (Heidenreich et al., 2011) . Plasma microparticles proteins that can be transferred to other cell types to promote either deleterious or beneficial effects such as endothelial activation and inflammation or endothelial differentiation and survival, respectively (Dignat-George & Boulanger, 2011; Paudel et al., 2016; Puddu, Puddu, Cravero, Muscari, & Muscari, 2010) . Elevations in MP levels may provide important clinical information regarding the extent of vascular disruption in individuals with chronic stroke. For example, endothelial vasoreactivity as measured by flow-mediated dilatation is inversely related to plasma MP levels, independent of age (Chironi et al., 2009; Esposito et al., 2006b) . Furthermore, greater carotid-femoral pulse wave velocity measures of arterial stiffness are associated with higher circulating MP concentrations in healthy adults (Wang et al., 2007) . Thus, MPs both serve as biomarkers of vascular stress and potentially promote downstream signalling through transport of biological material (Abid Hussein et al., 2008; Chironi et al., 2009; Dignat-George & Boulanger, 2011; Lacroix et al., 2007; Sabatier et al., 2002) or interaction with membrane bound cellular receptors (Zhang et al., 2015) .
Although the precise mechanisms contributing to MP release are not completely understood, the circulating concentration and type of MP (i.e. surface markers present) may provide an index of the extent and nature of cellular damage, respectively. For example, one subset of MPs, CD31 + /CD42b − MPs, contain endothelial surface markers of non-platelet origin, which in vitro studies indicated are shed by endothelial cells as a result of apoptosis (Chironi et al., 2009; Horstman, Jy, Jimenez, & Ahn, 2004) . High circulating concentrations of CD31 + /CD42b − MPs are associated with clinical conditions including hypertension (Preston et al., 2003; Viera, Mooberry, & Key, 2012) and play a major role in the atherosclerotic process (Paudel et al., 2016) . CD62E + MPs, on the other hand, although also of endothelial origin, are released in response to cellular activation (for example, exposure to elevated levels of TNF-). While CD62E + MPs are present even in healthy individuals (Berkmans et al., 2001) , elevated MP numbers are seen in various cardiometabolic conditions and in association with cardiovascular risk (Babbitt et al., 2013; Lee et al., 2012) . Indeed, Lee et al. found that high CD62E + MP number in chronic stroke survivors was associated with greater risk of major cardiovascular events and hospitalization within 3 years after their stroke (Lee et al., 2012) . Finally, CD34 + MPs are derived from haematopoetic progenitor and endothelial cells. The CD34 surface marker on haematopoietic cells is often associated with pro-angiogenic functions. Like CD34 + haematopoetic cells, CD34 + MPs are elevated in acute coronary syndrome patients compared to those adults with stable angina and healthy controls (Stepien et al., 2012) . Despite the few studies suggesting CD34 + MPs as biomarkers with potential proangiogenic properties, this MP population has not been well explored.
Given the potential roles of these three types of circulating MPs in maintaining vascular homeostasis, their study in people with chronic stroke and associated risk factors is warranted.
Stroke is particularly prevalent in older adults and is associated with a number of other cardiometabolic complications. Along with macrovascular complications associated with chronic stroke (Ivey, Hafer-Macko, Ryan, & Macko, 2010) , skeletal muscle atrophy of the paretic limb and associated reductions in skeletal muscle capillarization (Prior et al., 2009 ) often lead to the development of insulin resistance (Prior et al., 2009 ) and reduced cardiovascular fitness (Billinger, Coughenour, MacKay-Lyons, & Ivey, 2012; Ryan, Dobrovolny, Silver, Smith, & Macko, 2000) . Indeed, more than 75% of individuals with chronic stroke have impaired glucose tolerance or type 2 diabetes mellitus (T2DM) (Ivey et al., 2006) . While there are several studies that have examined the effects of an acute stroke on
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• What is the central question of this study?
What is the effect of chronic stroke on circulating microparticle populations, accounting for potential effects of age and type 2 diabetes?
• What is the main finding and its importance?
Elevated concentrations of CD31 + /CD42b − and CD62E + microparticles appear to be driven by type 2 diabetes but not chronic stroke and are associated with fasting glucose and triglyceride levels. Older age results in elevations in CD62E + and CD34 + microparticle concentrations.
These microparticles have been proposed as potential targets for diagnosing, treating and identifying the clinical progression and complications of type 2 diabetes. different MP populations (Cherian et al., 2003; Chiva-Blanch et al., 2016; Jung et al., 2009; Simak et al., 2004; Simak, Gelderman, Yu, Wright, & Baird, 2006; Williams, Jauch, Lindsell, & Campos, 2007) , only one, to our knowledge, has looked at the MP response in chronic stroke survivors. Lee et al. (2012) found that high circulating CD62E + MPs are associated with greater CVD risk in chronic stroke but it is unknown whether this occurs independently of older age or insulin resistance. The purpose of this study was to determine circulating concentrations of CD31 + /CD42b − , CD62E + and CD34 + MPs in chronic stroke patients compared with healthy, young controls, while accounting for potential effects of age and T2DM by also studying groups of healthy older adults and older adults with T2DM. We hypothesized a graduated effect with chronic stroke patients having the highest MP concentrations, followed by T2DM, healthy older and healthy younger controls. We then sought to determine whether traditional CVD risk factors (i.e. plasma lipoprotein-lipid and glucose concentrations) were associated with concentrations of each MP subtype. A greater understanding of factors associated with older age with and without cardiometabolic disease may help establish MPs as novel clinical biomarkers for CVD risk.
METHODS
Ethical approval
The University of Maryland College Park (UMCP) and the University 
Screening and standard assessments
Subjects were recruited from the greater Baltimore and Washington, DC area. All subjects were sedentary completing ≤20 min of exercise on ≤2 days per week. Chronic stroke, T2DM and older healthy subjects were sedentary men and women 50-75 years old (the latter postmenopausal for >2 years and not prescribed hormone replacement therapy). Chronic stroke subjects had suffered an ischaemic stroke >3 months prior to testing and had completed all conventional physical therapy. T2DM subjects had either a diagnosis of type 2 diabetes, or a HbA 1C value of >6.5%, or a fasting glucose >126 mg dl −1 on two or more occasions (American Diabetes Association, 2018).
Chronic stroke and T2DM subjects were not excluded due to other chronic conditions including high blood pressure, hyperlipidaemia or hyperglycaemia, and these conditions and accompanying medications were documented. Healthy older adults were of similar age to the chronic stroke and T2DM groups but had blood pressure, and plasma lipid and glucose levels in the normal ranges. Younger adults were sedentary men and women 18-39 years old. Younger women were all tested during the early follicular phase of their menstrual cycle. Exclusion criteria for the healthy groups were: smoking, known CVD, type 1 or type 2 diabetes, chronic obstructive pulmonary disease, current treatment for active cancer, systolic blood pressure ≥130 mmHg; diastolic blood pressure ≥90 mmHg; serum total cholesterol ≥200 mg dl −1 ; low density lipoprotein-cholesterol (LDL-C) ≥130 mg dl −1 ; high-density lipoprotein-cholesterol (HDL-C) ≤35 mg dl −1 ; or fasting glucose ≥100 mg dl −1 .
Peak oxygen consumption
Peak oxygen consumption (V O 2 peak ) was measured by indirect calorimetry (Quark, Cosmed USA, Chicago, IL, USA) during a graded treadmill exercise test on a motorized treadmill. Subjects walked at a constant velocity with the grade initially set to 0% and increasing 4% after the first 2 min and 2% every 2 min thereafter to volitional exhaustion, as reported previously (Ivey, Ryan, Hafer-Macko, Goldberg, & Macko, 2007; Prior et al., 2009 ). Tests were terminated at the subject's request or according to criteria set forth by American College of Sports Medicine (Pescatello, Arena, Riebe, & Thompson, 2014) . Subjects were allowed handrail support but were instructed to minimize handrail use to that necessary to maintain balance.V O 2 peak was defined as the highest oxygen consumption value obtained in the last minute of exercise.
Fasted blood draw
Subjects reported to the lab the morning after an overnight (12 h) fast. They were asked to refrain from food, alcohol and caffeine until after the blood draw. Height, weight and seated blood pressure were recorded after arriving at the lab. Blood was collected in tubes containing 15% potassium EDTA; plasma was isolated for measurement of lipoprotein-lipid levels and plasma for MP measures was isolated and stored at −80 • C until future analysis.
Blood sample analyses
Plasma glucose levels were measured in duplicate using the glucose oxidase method (2300 STAT Plus, YSI, Yellow Springs, OH, USA).
Plasma triglyceride (TG) and cholesterol were analysed by enzymatic methods (Hitachi mofel-917 analyser). HDL-C was measured in the supernatant after precipitation with dextran sulfate and LDL-C was calculated using the Friedewald equation (Friedewald, Levy, & Fredrickson, 1972) 
Plasma microparticles
MP quantification and analysis was performed as previously described (Jenkins et al., 2011) with minor modifications. Briefly, plasma samples were thawed and platelet-poor plasma was obtained through centrifugation. Platelet-poor plasma was then further centrifuged to obtain cell-free plasma (CFP), which was used for MP analyses. Fifty microlitres of CFP was incubated with anti-CD31-phycoerythrin (PE) and anti-CD42b-fluorescein isothiocyanate (FITC), anti-CD62E-PE or anti-CD34-FITC (BD Biosciences, San Jose, CA, USA) for 30 min.
Samples were then fixed with 2% paraformaldehyde and diluted with filtered phosphate-buffered saline before flow cytometric analysis.
Microparticle quantification and analysis
MP quantification was performed using an LSR II flow cytometer with a lower detection limit of 0.5 m. Samples were each analysed for 3 min at a medium flow rate. Countbright Absolute Counting Beads (Thermo Fisher Scientific, Waltham, MA, USA) were added to each sample immediately before quantification and ultra-pure water was run for 1 min in between each sample. MPs were defined as CD31 + CD42b − , CD62E + or CD34 + events between 0.5-1.0 m, excluding exosomes and other small microvesicles from analyses (Gould & Raposo, 2013) . 
Statistical analysis
Statistical analyses were completed using SPSS Statistics version 21
(IBM Corp., Armonk, NY, USA). Assumptions of homoscedasticity and normality were evaluated for all measures. MP data were logtransformed for statistical analyses due to a non-normal distribution of residuals in raw data. Differences among groups were compared using ANOVA. For our main analyses, power calculations using previous cross-sectional comparisons of MPs in populations with various levels of CVD risk factors (Lansford et al., 2016; Preston et al., 2003 ) estimated a sample size of n = 11/group to yield detectable differences and 80% power. As 41% of chronic stroke subjects were 
RESULTS
Subject characteristics
Subject characteristics can be found in Table 1 . By design, the chronic stroke, T2DM and healthy older groups were significantly older than the younger group; these three groups also had higher BMI values compared with the younger adults (P < 0.05). There were no significant differences in age or BMI among the three older groups (chronic stroke, T2DM and healthy older). All older groups exhibited significantly lower absolute and relativeV O 2 peak compared with younger adults, with chronic stroke subjects having the lowestV O 2 peak values (P < 0.05).
Both HbA1c and fasting glucose were highest in the T2DM group and all three older groups exhibited significantly higher glucose levels compared with healthy younger adults. HbA1c levels were 7.5 ± 0.85% in the stroke (diabetes + ) group and 5.5 ± 0.12% in stroke (diabetes − ) group, which are similar to their T2DM and healthy older counterparts, respectively. The T2DM group had significantly higher triglycerides and significantly lower HDL-C levels compared with both healthy younger and older adults (P < 0.05 for both). All subjects in the chronic stroke group and T2DM group were on at least one statin and/or blood pressure medication and 88% of subjects diagnosed with T2DM were prescribed medications to control diabetes ( 2.5 ± 0.6* 2.5 ± 0.6* 3.2 ± 0.9
V O 2 peak (ml kg −1 min −1 ) 18.7 ± 4.5* † ‡ 25 ± 4.9* 26 ± 7.5* 44 ± 8.9
Means ± SD. * Significantly different from healthy younger (P < 0.05). † Significantly different from healthy older (P < 0.05). ‡ Significantly different from T2DM (P < 0.05). 
TA B L E 2 Medications
Medication
CD62E + microparticles
Compared with young adults, CD62E + MP concentrations were significantly higher in all older groups (122%, 179% and 393%, in 
P=0.08
F I G U R E 3
Comparison of CD31 + /CD42b − (a), CD62E + (b) and CD34 + (c) microparticle (MP) concentrations in chronic stroke (diabetes − ) (n = 10), type 2 diabetes mellitus (T2DM) (n = 17), and healthy older (n = 17) and younger individuals (n = 17). Inset figures represent comparison between chronic stroke (diabetes + ) (n = 7) and chronic stroke (diabetes − ) (n = 10). Raw data are presented but were log-transformed for analyses. Data represent mean and 95% confidence limits. *Significantly different from healthy younger adults (P < 0.05); †significantly different from healthy older adults (P < 0.05); ‡significantly different from T2DM (P < 0.05) healthy (P = 0.03), chronic stroke (P = 0.02) and T2DM subjects (P = 0.005), respectively; Figure 2a ). Furthermore, CD62E + MP concentrations were higher in the T2DM group compared with healthy older adults (P = 0.03, Figure 2b ). Analyses of chronic stroke subjects with and without diabetes indicated that the stroke (diabetes + ) had 37% more CD62E + MPs compared with stroke (diabetes − ), although this did not reach statistical significance (P = 0.23). Sub-analyses indicated a tendency for 101% higher CD62E + MPs in the T2DM compared with the stroke (diabetes − ) (P = 0.08; Figure 3b ).
CD34 + microparticles
There was an effect of age on CD34 + MP concentrations, with healthy older adults (P = 0.02), chronic stroke (P = 0.01) and T2DM (P = 0.01) subjects having significantly higher CD34 + MP concentrations than healthy younger individuals (61%, 47% and 99% higher, respectively; Figure 2c ). No additional effect of T2DM or chronic stroke was observed (P = 0.36 and P = 0.38 for both). CD34 + MP concentrations did not differ between stroke subjects with and without diabetes and sub-analyses of stroke (diabetes − ) were consistent with findings from original analyses (P = 0.92; Figure 3c ). Chronic stroke is associated with long-term vascular consequences that extend far beyond the cerebrum into the periphery (Alexandrova & Bochev, 2005; Banerjee & Chimowitz, 2017; Billinger et al., 2012) and include reduced endothelial vasoreactivity (Ivey et al., 2010 ) and capillary rarefaction (Prior et al., 2009) , most notably in the paretic limb. These vascular complications could, in part, be attributed to MPs with pro-inflammatory effects as we hypothesized that chronic stroke would have elevated MP concentrations compared with other groups. As expected, all three MP subtypes were higher in the chronic stroke group compared with the younger adults. However, we found no differences in any of the three MP subtypes between chronic stroke and the other two older groups (T2DM or healthy older) in our primary analyses. In this study, the degree of hemiparesis was not quantified in the individuals with chronic stroke, but it is possible that MP and other outcomes could vary within this population as a function of the degree of hemiparesis. Impaired glucose metabolism is highly prevalent in chronic stroke (Ivey et al., 2007; Prior et al., 2009 ) and 42% of the subjects in our chronic stroke group were also diagnosed with T2DM. Therefore, we performed additional analyses in which we excluded all chronic stroke subjects who were also diagnosed with diabetes (i.e. stroke (diabetes − ) vs. T2DM group). Interestingly, the stroke (diabetes − ) group had significantly lower CD31 + /CD42b − and there was a trend for lower CD62E + MPs compared with the T2DM group. Our findings indicate that the presence of T2DM, and not the effects of chronic stroke itself, appears to explain the elevations in CD31 + /CD42b − and CD62E + MPs in the present report.
Relationships among MP concentrations and CVD risk factors
DISCUSSION
T2DM is associated with disturbances in metabolism and vascular function (Deng, Wang, & Zhang, 2016) which could be partially attributable to concentrations of specific MPs. We found that CD31 + / CD42b − and CD62E + MPs were highest in subjects with T2DM compared with healthy older and younger groups. Other studies have also found that CD31 + /CD42b − MP levels are higher in men with T2DM compared with controls (Esposito et al., 2007; Leroyer, Tedgui, & Boulanger, 2008) and that they are predictive of macrovascular complications in T2DM (Jung et al., 2011) . However, there are currently few studies demonstrating alterations in CD62E + MPs in subjects with T2DM (Esposito et al., 2007) . Our findings suggest that MPs associated with endothelial apoptosis and activation are more elevated in T2DM than in chronic stroke or older age alone. In an effort to gain insight into systemic factors that may be involved in MP release from the endothelium, we performed regression analyses among the three MP subtypes and levels of physical fitness, plasma lipids, BMI and glucose, and found that CD31 + /CD42b − and CD62E + MPs directly correlated with fasting glucose levels. These findings are congruent with previous in vitro work demonstrating that a high glucose environment induces endothelial cell apoptosis (Baumgartner-Parzer et al., 1995) and endothelial activation (Videm & Albrigtsen, 2007) as well as in vivo findings that hyperglycaemia is associated with greater CVD risk (Tabit, Chung, Hamburg, & Vita, 2010) . Additionally, we found that triglyceride levels directly correlated with CD31 + /CD42b − MP concentrations, which supports hypertriglyceridaemia's known association with endothelial impairments (Lundman et al., 2003) . The present findings are congruent with other reports of direct associations between CD31 + /CD42b − MP and triglyceride levels (Amabile et al., 2014; Ferreira et al., 2004) , and extend those findings by demonstrating elevated MPs in subjects with more chronic, lower-grade elevations in fasting triglycerides. Conversely, regression analyses found no association between CD62E + and fasting triglyceride levels. In the current study, the T2DM group exhibits the highest triglyceride and glucose levels of all groups. Although triglyceride levels are still within the normal range, this is likely to be pharmacologically induced as all T2DM subjects were prescribed statins, potentially influencing our results. It seems likely that a combination of various metabolic imbalances (elevated glucose, triglycerides and lower HDL-C) contribute to endothelial apoptosis, which leads to greater MP release in the T2DM group.
There are several differences between the current and previous studies on MPs. First, subjects in our study represent a wider range of age and health including chronic stroke and T2DM. Additionally, it is important to note that 76% of chronic stroke subjects and all T2DM subjects in our study were on some form of diabetes medication, statin or lipid lowering medication. Some medications have been found to influence specific MP concentrations with studies indicating that statins either increase (Diamant et al., 2017) or decrease (Tramontano et al., 2004) different MPs in vitro and some medications resulting in lower MP concentrations in individuals with diabetes and hypertension (Esposito, Ciotola, & Giugliano, 2006a; Nomura et al., 2007; Nomura et al., 2009; Nomura, Shouzu, Omoto, Nishikawa, & Iwasaka, 2005) . Due to their necessity in these populations we were unable to withhold medications for longer than the 12 h fasting period and the use of medications may have influenced some of our findings.
More research is needed to better understand the effects of individual medications and the combined effects of multiple medications on MP concentrations. Finally, it is worth noting that HDL-C levels in our subjects were surprisingly high, especially in the chronic stroke group, with only T2DM subjects having significantly lower HDL-C levels compared with healthy younger adults. This is likely a result of statin usage in the chronic stroke population. HDL cholesterol is involved in the transport of cholesterol from the arteries; thus, it is possible that the relatively high HDL-C levels attenuated endothelial impairment and MP production in the chronic stroke population.
A strength of this study is the balance of sex across groups, although the relatively low female participation prevented an examination of sex differences in MP concentrations from each group. Some recent studies have begun to examine these issues, although the sex differences remain unclear with some studies reporting lower and others higher resting levels of CD62E + MPs in sedentary younger women compared with men (Durrer et al., 2015; Gustafson et al., 2015) .
In addition, some studies are beginning to explore MP responses to an acute bout of aerobic exercise and find differential responses between men and women in CD62E + (Durrer et al., 2015; Lansford et al., 2016; Shill et al., 2018) and CD34 + MPs (Lansford et al., 2016) , suggesting sex differences in responses to vascular stressors with exercise. Thus, future studies specifically designed to examine mechanisms related to sex differences in various populations and in response to an exercise or nutritional intervention might provide better indication as to the use of MPs as sex-specific biomarkers of CVD risk.
Because the present study was limited to correlation analyses of relationships among CD31 + /CD42b − and CD62E + MP concentrations and triglycerides or glucose, it cannot provide specific mechanistic evidence of the effects of these factors on MPs (or vice versa). Future studies are needed to investigate molecular pathways involved in dislipidaemia and hyperglycaemia, how these relate to MP production, and potential mechanisms through which MPs may further be involved in disease pathology to fully understand the complex roles of different MP subtypes. Additionally, we are unable to present the time frame since diagnosis of T2DM for all our subjects, which might play a role in the extent of vascular stress and consequently, MP concentration.
Future work documenting the concentration of different MP subtypes at different stages of T2DM diagnosis would allow for a better understanding of the disease process and how MPs are involved. Recent work has demonstrated that diet, specifically low-carbohydrate diet, can affect MP concentrations in T2DM (Francois et al., 2018) . Subjects in the current study arrived fasted but diet was not controlled leading up to their visit, which may have affected our outcomes. The current study was designed as a cross-sectional analysis of the levels of three MP subtypes. Further classification of MPs including analyses of MP content and activity as well as their direct effects on endothelial function and whether this can be modified are necessary to fully understand the nature and actions of these factors. It should be acknowledged that plasma was obtained using EDTA anticoagulant.
Although ACD anticoagulant is preferred (Golanski, Pietrucha, Baj, Greger, & Watala, 1996; Gyorgy et al., 2014; Jayachandran, Miller, Heit, & Owen, 2012) , we (Jenkins et al., 2011) and others (Babbitt et al., 2013 ) have successfully quantified MPs using EDTA plasma. Thus, while this may limit our ability to compare specific concentrations of MPs to some other studies, observations of trends for differences in MP levels among similar populations are possible. The samples used in this study were collected on different dates and stored frozen prior to analysis, which can influence MP concentrations (Dey-Hazra et al., 2010) . The storage times varied within all groups, but were not likely different among groups. However, analyses of MP degradation would allow for a better understanding of whether potential differences in storage times affected our outcomes. Finally, we acknowledge that the sub-analyses of stroke (diabetes − ) included a lower sample size, and thus, may not be adequately powered. This may explain why significant differences between the stroke (diabetes + ) and stroke (diabetes − ) groups were not detected. While these findings may prove physiologically significant, larger studies are needed to confirm the effects of stroke with and without the presence of diabetes.
In conclusion, our study demonstrates that elevations in 
